These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 3802118)

  • 1. Phase II trial of 1,2,4-triglycidylurazol in patients with metastasized renal cell carcinoma.
    Wagner H; Possinger K; Bremer K; Donhujsen-Ant R; Peukert M; Queisser W
    Cancer Treat Rep; 1987 Feb; 71(2):209-10. PubMed ID: 3802118
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II study of thymosin fraction 5 in the treatment of metastatic renal cell carcinoma.
    Dimitrov NV; Arnold D; Munson J; Singh T; Borst J; Stott P
    Cancer Treat Rep; 1985 Jan; 69(1):137-8. PubMed ID: 3967256
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II trial of taxol in patients with metastatic renal cell carcinoma.
    Einzig AI; Gorowski E; Sasloff J; Wiernik PH
    Cancer Invest; 1991; 9(2):133-6. PubMed ID: 1677827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II evaluation of mitoxantrone in advanced renal cell carcinoma: a Southeastern Cancer Study Group Trial.
    Gams RA; Nelson O; Birch R
    Cancer Treat Rep; 1986 Jul; 70(7):921-2. PubMed ID: 3521848
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase II trial of sequential radiation and interleukin 2 in the treatment of patients with metastatic renal cell carcinoma.
    Redman BG; Hillman GG; Flaherty L; Forman J; Dezso B; Haas GP
    Clin Cancer Res; 1998 Feb; 4(2):283-6. PubMed ID: 9516912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of streptozocin in the treatment of advanced renal cell carcinoma.
    Licht JD; Garnick MB
    Cancer Treat Rep; 1987 Jan; 71(1):97-8. PubMed ID: 2947680
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase II study of carboxyamidotriazole in patients with advanced renal cell carcinoma refractory to immunotherapy: E4896, an Eastern Cooperative Oncology Group Study.
    Dutcher JP; Leon L; Manola J; Friedland DM; Roth B; Wilding G;
    Cancer; 2005 Dec; 104(11):2392-9. PubMed ID: 16222691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of 10-deazaaminopterin for advanced hypernephroma.
    Scher HI; Yagoda A; Ahmed T; Hollander P; Watson RC
    Anticancer Res; 1984; 4(6):409-10. PubMed ID: 6517533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of renal cell carcinoma with alpha (human leukocyte) interferon and vinblastine in combination: a phase I-II trial.
    Figlin RA; deKernion JB; Maldazys J; Sarna G
    Cancer Treat Rep; 1985 Mar; 69(3):263-7. PubMed ID: 3978656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapy for advanced renal cell cancer with spirogermanium: a Southwest Oncology Group Study.
    Saiers JH; Slavik M; Stephens RL; Crawford ED
    Cancer Treat Rep; 1987 Feb; 71(2):207-8. PubMed ID: 3802117
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.
    Davis NB; Taber DA; Ansari RH; Ryan CW; George C; Vokes EE; Vogelzang NJ; Stadler WM
    J Clin Oncol; 2004 Jan; 22(1):115-9. PubMed ID: 14701773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of elliptinium in advanced renal cell carcinoma.
    Caillé P; Mondesir JM; Droz JP; Kerbrat P; Goodman A; Ducret JP; Theodore C; Spielman M; Rouëssé J; Amiel JL
    Cancer Treat Rep; 1985; 69(7-8):901-2. PubMed ID: 4016798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma.
    Amato RJ; Morgan M; Rawat A
    Cancer; 2006 Apr; 106(7):1498-506. PubMed ID: 16475152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma.
    Hainsworth JD; Infante JR; Spigel DR; Arrowsmith ER; Boccia RV; Burris HA
    Cancer Invest; 2011 Aug; 29(7):451-5. PubMed ID: 21696296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study.
    Haas NB; Smith M; Lewis N; Littman L; Yeslow G; Joshi ID; Murgo A; Bradley J; Gordon R; Wang H; Rogatko A; Hudes GR
    Clin Cancer Res; 2003 Jan; 9(1):109-14. PubMed ID: 12538458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treosulfan in the treatment of metastatic renal cell carcinoma.
    Rigos D; Wechsel HW; Bichler KH
    Anticancer Res; 1999; 19(2C):1549-52. PubMed ID: 10365143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of methotrexate-human serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who progressed under immunotherapy.
    Vis AN; van der Gaast A; van Rhijn BW; Catsburg TK; Schmidt C; Mickisch GH
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):342-5. PubMed ID: 11914915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chemotherapy of metastatic renal cell carcinoma with cis-diamminedichloroplatinum and other drugs].
    Okumura S; Nishimura T; Yoshida K; Ohhara M; Hasegawa J; Hirasawa S; Hara M; Kawamura N; Kanamori S; Akimoto M
    Hinyokika Kiyo; 1984 Sep; 30(9):1167-71. PubMed ID: 6084420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.
    Samuels BL; Hollis DR; Rosner GL; Trump DL; Shapiro CL; Vogelzang NJ; Schilsky RL
    Clin Cancer Res; 1997 Nov; 3(11):1977-84. PubMed ID: 9815587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose interleukin-2 in metastatic renal cell carcinoma.
    Fernández-Rodríguez R; de Argumedo GL; Mañé JM; Muñoz A; Ferreiro J; Fuente N; López-Vivanco G
    J Clin Oncol; 2005 Sep; 23(27):6797-8; author reply 6798-9. PubMed ID: 16170190
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.